Torrent Pharmaceuticals Ltd

BSE: 500420 NSE: TORNTPHARM
Torrent Pharmaceuticals Ltd - pharma in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
CIN L24230GJ1972PLC002126 Incorporated 15 July 1972 ROC Ahmedabad HQ Ahmedabad, Gujarat, India
Active Listed - NSE: TORNTPHARM · BSE: 500420 Public Limited Company pharma Fortune India 500 · #229 Nifty 500
Data last updated
Market Cap
₹1,75,920 Cr
TORNTPHARM · NSE
Share Price
₹4,557.00
-1.47% today
Revenue
₹19,274 Cr
FY 2025-26 · +67.4% YoY
EBITDA
₹4,470 Cr
Margin 23.2%
Net Profit
₹2,192 Cr
FY 2025-26 · +14.4% YoY
P/E (TTM)
77.1x
P/B 20.5x
ROE
26.8%
ROCE 18.3%
Debt / Equity
1.14
Interest cover 11.5x

About Torrent Pharmaceuticals Ltd

Data last updated:

Torrent Pharmaceuticals Ltd is a public limited company based in Ahmedabad, Gujarat, India, a subsidiary of Torrent Investments Private Limited. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 15 July 1972 and has been in existence for over 54 years.

Torrent Pharmaceuticals is ranked #229 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director Samir Mehta and family are #10 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24230GJ1972PLC002126. Its GSTIN is 24AAACT5456A1ZR (Gujarat). The company holds 40 GST registrations, of which 25 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 500420 and NSE: TORNTPHARM.

The company has an authorised share capital of ₹235 Cr and a paid-up capital of ₹169.22 Cr. It was formerly known as Torrent Laboratories Private Limited and Torrent Pharmaceuticals Pvt Ltd. It is led by directors including Samir Uttamlal Mehta (Managing Director) and Aman Samir Mehta (Managing Director).

Its last annual general meeting (AGM) was held on 28 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Avirat, Thaltej Shilaj Road Ahmedabad, Gujarat, India – 380059.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹19,274 Cr, a growth of 67.4% compared to the previous year. For the same year it recorded a net profit of ₹2,191.62 Cr (net margin 11.4%) and EBITDA of ₹4,469.71 Cr (EBITDA margin 23.2%). The net worth stands at ₹8,388.43 Cr (up 10.5% YoY). Total assets are valued at ₹33,483 Cr (up 196.1% YoY).

The company has about 15,615 employees on its provident fund (EPFO) records.

The company is associated with 2 brands: Tedibar and Torrent Pharma. As per MCA filings, the company has open charges of ₹13,352 Cr and satisfied charges of ₹10,034 Cr on record. Court records list 472 cases involving the company, including 219 filed by the company and 253 filed against it; 138 cases are pending. The company has 50 deals on record (37 market trades, 13 secondary share transfers); the latest was in January 2025. Its 9 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Hetero Labs Limited with revenue of ₹16,537 Cr. The company has 12 MSME Form 1 returns on record between 2018 and 2024, listing 185 overdue payments to 76 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website torrentpharma.com.

Company details

CIN L24230GJ1972PLC002126
Registration Number 002126
Incorporation Date 15 July 1972
ROC Ahmedabad
Listing Status Listed - Listed on NSE (TORNTPHARM); Listed on BSE (500420)
Company Status Active
Date of Last AGM 28 July 2025
Date of Balance Sheet 31 March 2026
Parent Company Torrent Investments Private Limited
Compliance Status Active Compliant

Name history

Torrent Pharmaceuticals has undergone 2 name changes throughout its history. The company was previously known as Torrent Laboratories Private Limited, and Torrent Pharmaceuticals Pvt Ltd. The current legal name is Torrent Pharmaceuticals Ltd.

Company NameStatus
Torrent Pharmaceuticals LtdCurrent
Torrent Laboratories Private LimitedPrevious
Torrent Pharmaceuticals Pvt LtdPrevious
Key People
Samir Uttamlal Mehta Managing Director Aman Samir Mehta Managing Director Nayantara Bali Director

Recognitions & Rankings of Torrent Pharmaceuticals

Fortune India 500 2025 edition
Rank#229
Total income
₹11,814 Cr
Profit
₹1,911 Cr
Last year #220
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#54
Valuation
₹1,12,910 Cr
2023 #68 2022 #69 2021 #89
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 500 BSE 500

Contact details

Torrent Pharmaceuticals Ltd's registered office is in Ahmedabad, Gujarat. Its website is torrentpharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    torrentpharma.com
  • Social Media
  • Registered Address
    Avirat, Thaltej Shilaj Road Ahmedabad, Gujarat, India – 380059
  • Industry
    Pharma, Drug Formulation & Development

To see the full contact details of Torrent Pharmaceuticals Ltd, buy the company report.

Comprehensive company report
Torrent Pharmaceuticals Ltd - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Torrent Pharmaceuticals operates two associated brands: Tedibar and Torrent Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Tedibar
Offers gentle, moisturizing baby bathing bars and washes for sensitive skin care.tedibar.com
Torrent Pharma
Formulations, APIs, drug discovery, marketing, and sales services are provided.torrentpharma.com

Business activity

The main business activity of Torrent Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Torrent Pharmaceuticals Ltd, buy the company report.

Financials of Torrent Pharmaceuticals Ltd

FY 2025-26 filings available

Torrent Pharmaceuticals Ltd reported revenue of ₹19,274 Cr (up 67.4% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹19,274 Cr
+67.4% YoY
EBITDA
₹4,470 Cr
+20.9% YoY
Profit After Tax
₹2,192 Cr
+14.4% YoY
Net Worth
₹8,388 Cr
+10.5% YoY
Total Assets
₹33,483 Cr
+196.1% YoY
Total Debt
₹15,026 Cr
+369.2% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue19,27411,51610,7289,6208,5088,0057,939
Revenue growth+67.4%+7.4%+11.5%+13.1%+6.3%+0.8%-
EBITDA4,4703,6973,3682,8421,9472,4802,170
EBITDA margin+23.2%+32.1%+31.4%+29.5%+22.9%+31.0%+27.3%
Profit before tax2,8722,6732,3521,8471,2261,5261,187
Net profit2,1921,9161,5811,2181,0761,2401,002
Net profit margin+11.4%+16.6%+14.7%+12.7%+12.7%+15.5%+12.6%
EPS (₹)63.9256.4748.9436.7945.9273.9760.55
Balance sheet
Total assets33,48311,30911,33311,98210,40111,09411,065
Net worth8,3887,5916,8566,1985,9535,8374,823
Total debt15,0263,2024,0225,3694,0704,8745,784
Cash & bank1,165579839571403604667
Net working capital3,3672,6582,3992,5302,4762,4022,034
Cash flow
Cash from operations3,0232,5853,2662,3681,8032,0051,393
Cash from investing(12,630)(549)(160)(2,335)(196)(444)229
Cash from financing10,151(2,298)(2,780)77.36(1,781)(1,651)(1,549)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,9794,9214,1973,3033,3023,1782,9592,809
Revenue growth (YoY)+50.8%+54.9%+41.8%+17.6%+14.3%+11.2%--
Other income(10.00)(12.00)(17.00)(13.00)(27.00)(37.00)(18.00)33.00
EBITDA1,6561,6431,2901,0781,0701,032940914
EBITDA margin+33.8%+34.0%+31.3%+33.2%+33.0%+33.0%+32.3%+33.1%
Depreciation609593508206204201201199
Interest30030523645.0048.0056.0056.0057.00
Profit before tax737733529814791738665691
Tax203167165179200190167188
Net profit534566364635591548498503
EPS (₹)14.0514.8711.5118.7717.4516.1914.7114.88
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue10,7139,6838,5337,6956,7426,4516,168
Revenue growth+10.6%+13.5%+10.9%+14.1%+4.5%+4.6%-
EBITDA3,9833,5522,8892,4652,1012,1921,917
EBITDA margin+37.2%+36.7%+33.9%+32.0%+31.2%+34.0%+31.1%
Profit before tax2,8972,6101,9171,5771,4661,3661,117
Net profit2,2131,8921,3421,0239851,125914
Net profit margin+20.7%+19.5%+15.7%+13.3%+14.6%+17.4%+14.8%
EPS (₹)64.7555.7840.1031.0658.5867.2355.45
Balance sheet
Total assets23,18210,57410,46511,2989,91110,63510,667
Net worth8,4527,5926,8296,4566,3456,0305,121
Total debt14,2772,6293,3444,5753,3484,4045,294
Cash & bank82.9811010914869.4666.42391
Net working capital2,8972,7972,3452,5992,7012,8772,602
Cash flow
Cash from operations2,7312,5742,8932,2652,1401,5731,580
Cash from investing(12,990)(470)(296)(2,326)(160)(316)269
Cash from financing10,225(2,104)(2,578)80.74(1,977)(1,581)(1,555)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,1454,1583,4452,5992,7622,6162,4332,377
Revenue growth (YoY)+50.1%+58.9%+41.6%+9.3%+13.5%+7.3%--
Other income(11.00)(21.00)(30.00)(8.00)(27.00)(5.00)15.003.00
Total expenses2,5842,6062,2831,6091,7031,6371,5891,490
EBITDA1,5611,5521,1629901,059979844887
EBITDA margin+38.4%+38.1%+34.4%+38.9%+39.1%+38.1%+35.4%+38.1%
Depreciation587575490191189187190191
Interest28729322634.0037.0045.0047.0048.00
Profit before tax676663416757806742622651
Tax178171107180209191148166

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 28 Oct 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,9794,9214,1973,3033,3023,1782,9592,809
Revenue growth (YoY)+50.8%+54.9%+41.8%+17.6%+14.3%+11.2%--
Other income(10.00)(12.00)(17.00)(13.00)(27.00)(37.00)(18.00)33.00
EBITDA1,6561,6431,2901,0781,0701,032940914
EBITDA margin+33.8%+34.0%+31.3%+33.2%+33.0%+33.0%+32.3%+33.1%
Depreciation609593508206204201201199
Interest30030523645.0048.0056.0056.0057.00
Profit before tax737733529814791738665691
Tax203167165179200190167188
Net profit534566364635591548498503
EPS (₹)14.0514.8711.5118.7717.4516.1914.7114.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue19,27411,51610,7289,6208,5088,0057,939
Revenue growth+67.4%+7.4%+11.5%+13.1%+6.3%+0.8%-
Other income(93.58)23.2714645.1419756.91121
Total expenses14,8057,8197,3606,7786,5615,5245,769
Employee cost2,6712,2031,9841,6781,5261,4401,429
EBITDA4,4703,6973,3682,8421,9472,4802,170
EBITDA margin+23.2%+32.1%+31.4%+29.5%+22.9%+31.0%+27.3%
Depreciation1,119795808707662658654
Interest385252354333255353451
Profit before tax2,8722,6732,3521,8471,2261,5261,187
Tax734762696602449274162
Net profit2,1921,9161,5811,2181,0761,2401,002
Net profit margin+11.4%+16.6%+14.7%+12.7%+12.7%+15.5%+12.6%
EPS (₹)63.9256.4748.9436.7945.9273.9760.55
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16916916916984.6284.6284.62
Reserves & surplus8,2197,4216,6876,0295,8685,7534,739
Shareholders' funds (net worth)8,3887,5916,8566,1985,9535,8374,823
Minority interest9,1960.000.000.000.000.000.00
Secured loans12,6842,2263,1504,5303,2954,3325,180
Unsecured loans2,342976872839775542605
Total debt15,0263,2024,0225,3694,0704,8745,784
Total liabilities33,48311,30911,33311,98210,40111,09411,065
Assets
Gross block40,42614,04113,48512,81210,72810,51210,334
Net block33,1917,9478,1388,1216,4237,0657,533
Capital work in progress641478361765630889712
Investments9481561731992261812.11
Inventories3,1382,5412,2792,2302,4622,6812,148
Sundry debtors3,0311,8661,8441,9441,6321,5231,649
Cash & bank balances1,165579839571403604667
Loans & advances1,192523508413483574515
Total current assets8,5265,5105,4705,1584,9815,3824,979
Total current liabilities5,1592,8523,0722,6282,5052,9812,945
Net working capital3,3672,6582,3992,5302,4762,4022,034
Total assets33,48311,30911,33311,98210,40111,09411,065
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash573835509398573662589
Net cash from operating activities3,0232,5853,2662,3681,8032,0051,393
Net cash from investing activities(12,630)(549)(160)(2,335)(196)(444)229
Net cash from financing activities10,151(2,298)(2,780)77.36(1,781)(1,651)(1,549)
Net change in cash544(262)327110(174)(89.26)73.06
Closing cash1,165579839571403604667
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+67.4%+7.4%+11.5%+13.1%+6.3%+0.8%-
EBITDA growth+20.9%+9.8%+18.5%+46.0%-21.5%+14.3%-
PBT growth+7.5%+13.6%+27.3%+50.7%-19.7%+28.6%+111.3%
Net income growth+14.4%+21.2%+29.9%+13.1%-13.2%+23.7%-
Revenue CAGR (3Y)+26.1%+10.6%+10.3%+6.6%+3.5%+10.4%+10.9%
EBITDA CAGR (3Y)+16.3%+23.8%+10.7%+9.4%+6.2%+22.5%+16.4%
Profitability & leverage
Net income margin+11.1%+16.6%+15.4%+12.9%+9.1%+15.6%+12.9%
Return on capital employed+18.3%+25.8%+23.2%+19.5%+18.2%+17.0%+14.8%
Return on net worth+26.8%+26.5%+25.4%+20.5%+18.3%+23.5%+21.5%
Debt / equity1.140.500.720.780.761.001.24
Long-term debt / equity0.820.210.320.390.430.590.75
Interest cover11.498.6913.8115.6119.8619.3729.73
Efficiency & per share
Fixed asset turnover0.710.840.820.820.800.770.78
Inventory turnover6.794.784.764.103.313.313.89
Debtors turnover7.876.215.665.385.395.055.15
EPS (₹)63.9256.4748.9436.7945.9273.9760.55
Dividend per share (₹)38.0032.0028.0022.0048.0035.0032.00
Book value per share (₹)247.84224.27202.57183.13351.75344.90284.99
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue4,1454,1583,4452,5992,7622,6162,4332,377
Revenue growth (YoY)+50.1%+58.9%+41.6%+9.3%+13.5%+7.3%--
Other income(11.00)(21.00)(30.00)(8.00)(27.00)(5.00)15.003.00
Total expenses2,5842,6062,2831,6091,7031,6371,5891,490
EBITDA1,5611,5521,1629901,059979844887
EBITDA margin+38.4%+38.1%+34.4%+38.9%+39.1%+38.1%+35.4%+38.1%
Depreciation587575490191189187190191
Interest28729322634.0037.0045.0047.0048.00
Profit before tax676663416757806742622651
Tax178171107180209191148166
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue10,7139,6838,5337,6956,7426,4516,168
Revenue growth+10.6%+13.5%+10.9%+14.1%+4.5%+4.6%-
Other income17.9231.5091.3681.88204118237
Total expenses6,7306,1325,6445,2304,6424,2594,251
Employee cost1,8791,6361,4511,2511,0981,0971,062
EBITDA3,9833,5522,8892,4652,1012,1921,917
EBITDA margin+37.2%+36.7%+33.9%+32.0%+31.2%+34.0%+31.1%
Depreciation764759761672602610607
Interest341213303298236334430
Profit before tax2,8972,6101,9171,5771,4661,3661,117
Tax705722559526475228178
Net profit2,2131,8921,3421,0239851,125914
Net profit margin+20.7%+19.5%+15.7%+13.3%+14.6%+17.4%+14.8%
EPS (₹)64.7555.7840.1031.0658.5867.2355.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16916916916984.6284.6284.62
Reserves & surplus8,2837,4236,6606,2876,2615,9455,036
Shareholders' funds (net worth)8,4527,5926,8296,4566,3456,0305,121
Secured loans12,4942,0552,9834,3663,1434,1854,991
Unsecured loans1,782574361210204219303
Total debt14,2772,6293,3444,5753,3484,4045,294
Total liabilities23,18210,57410,46511,2989,91110,63510,667
Assets
Gross block13,85713,30113,00012,36710,0029,9539,806
Net block7,3707,5547,9867,9726,2516,7417,198
Capital work in progress420402226698568588536
Investments13,172523463361368314135
Inventories1,5261,5611,5661,6021,7971,9121,508
Sundry debtors2,6412,1711,5721,7291,5411,5441,509
Cash & bank balances82.9811010914869.4666.42391
Loans & advances514395354292342480412
Total current assets4,7644,2373,6003,7713,7494,0033,819
Total current liabilities1,8671,4401,2551,1721,0481,1261,218
Net working capital2,8972,7972,3452,5992,7012,8772,602
Total assets23,18210,57410,46511,2989,91110,63510,667
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash10510585.4065.0061.8738692.61
Net cash from operating activities2,7312,5742,8932,2652,1401,5731,580
Net cash from investing activities(12,990)(470)(296)(2,326)(160)(316)269
Net cash from financing activities10,225(2,104)(2,578)80.74(1,977)(1,581)(1,555)
Net change in cash(34.14)(0.05)19.4620.403.13(325)294
Closing cash82.9811010914869.4666.42391
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.6%+13.5%+10.9%+14.1%+4.5%+4.6%-
EBITDA growth+12.2%+22.9%+17.2%+17.4%-4.2%+14.3%-
PBT growth+11.0%+36.2%+21.5%+7.6%+7.3%+22.3%+19.4%
Net income growth+16.9%+41.0%+31.2%+3.9%-12.5%+23.1%-
Revenue CAGR (3Y)+11.7%+12.8%+9.8%+7.7%+5.4%+15.0%+10.7%
EBITDA CAGR (3Y)+17.3%+19.1%+9.7%+8.7%+9.2%+34.2%+19.4%
Profitability & leverage
Net income margin+20.5%+19.5%+15.9%+13.7%+14.7%+17.6%+15.2%
Return on capital employed+19.2%+26.8%+20.4%+17.7%+16.6%+16.0%+14.4%
Return on net worth+27.3%+26.2%+20.4%+16.4%+16.0%+20.4%+18.5%
Debt / equity1.050.410.600.620.630.871.08
Long-term debt / equity0.790.190.300.340.400.540.68
Interest cover10.597.6414.2416.6015.7721.1232.85
Efficiency & per share
Fixed asset turnover0.790.740.670.690.680.650.64
Inventory turnover6.946.195.394.533.643.774.30
Debtors turnover4.455.175.174.714.374.234.31
EPS (₹)64.7555.7840.1031.0658.5867.2355.45
Dividend per share (₹)38.0032.0028.0022.0048.0035.0032.00
Book value per share (₹)249.72224.32201.76190.75374.94356.30302.59

To see the full year-wise statements and ratios of Torrent Pharmaceuticals Ltd, buy the company report.

Board of directors of Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals has 7 current directors and 23 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Samir Uttamlal Mehta
Also directs: Radiant Urja LLP, Abhivyakti Enterprise LLP, Akalpya Enterprise LLP and 4 more
Managing Director01 Aug 201016 Years 2 MonthsCurrent
Nayantara Bali
Also directs: Marico Limited
Director07 Mar 20197 Years 7 MonthsCurrent
Manish Mahendra Choksi
Also directs: Asian Paints Limited, Vedant Fashions Limited, Birlasoft Limited and 5 more
Director29 Jul 20224 Years 2 MonthsCurrent
Ameera Sushil Shah
Also directs: Metz Advisory LLP, G&L Advisory LLP, Metropolis Healthcare Limited and 4 more
Director02 Aug 20188 Years 2 MonthsCurrent
Aman Samir Mehta
Also directs: Radiant Urja LLP, Torrent Investments Limited, Torrent Gujarat Titans Private Limited and 2 more
Managing Director31 Jul 20251 Years 2 MonthsCurrent
Jinal Sudhirbhai Mehta
Also directs: Radiant Urja LLP, Torrent Power Limited, Torrent Investments Limited and 4 more
Director24 May 20242 Years 5 MonthsCurrent
Showing 6 of 7 current directors. View all directors

Peer comparison

Torrent Pharmaceuticals Ltd is compared with the 9 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Torrent Pharmaceuticals Ltdthis company₹19,274 Cr (FY 2026)₹2,191.62 Cr11.4%67.4%15,615Ahmedabad, Gujarat, India
Hetero Labs Limited₹16,537 Cr (FY 2025)13.0%Hyderabad, Telangana, India
Biocon Limited₹16,470 Cr (FY 2025)5.0%Bengaluru, Karnataka, India
Alkem Laboratories Limited₹13,458 Cr (FY 2025)4.0%Mumbai, Maharashtra, India
Glenmark Pharmaceuticals Limited₹13,435 Cr (FY 2025)6.0%Mumbai, Maharashtra, India
Serum Institute of India Private Limited₹10,854 Cr (FY 2025)-2.0%Pune, Maharashtra, India
Macleods Pharmaceuticals Ltd₹9,671.68 Cr (FY 2025)5.0%Mumbai, Maharashtra, India
Ipca Laboratories Limited₹9,032.39 Cr (FY 2025)15.0%Mumbai, Maharashtra, India
Abbott Healthcare Private Limited₹8,811.32 Cr (FY 2025)3.0%Mumbai, Maharashtra, India
Emcure Pharmaceuticals Limited₹7,963.26 Cr (FY 2025)19.0%Pune, Maharashtra, India

To see the full peer comparison of Torrent Pharmaceuticals Ltd, buy the company report.

Auditor

Torrent Pharmaceuticals Ltd is audited by B S R & Co. LLP for the financial year 2024.

Auditor firmFinancial yearFirm registration number
B S R & Co. LLPFY 2024101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 68.30%, foreign institutional investors hold 15.40%, domestic institutional investors hold 9.90% and retail and other public shareholders hold 6.40%.

Promoters: 68.30%DII (Domestic Institutional): 9.90%FII (Foreign Institutional): 15.40%Retail & Others: 6.40%
Sep 2026
QUARTER
68.30% Promoters
9.90% DII (Domestic Institutional)
15.40% FII (Foreign Institutional)
6.40% Retail & Others
Promoter holding - history
Now 68.30% · Sep 2026High 68.30% · Dec 2025Low 68.30% · Dec 2025
67%67.8%68.5%69.3%70%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 68.30%Mar 2026: 68.30%Jun 2026: 68.30%Sep 2026: 68.30%68.30%68.30%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters68.30%68.30%68.30%68.30%
Public31.70%31.70%31.70%31.70%

Charges & borrowings

Open charges
₹13,352 Cr
Satisfied charges
₹10,034 Cr
Breakdown by lending institutions
Idbi Trusteeship Services Limited₹11,390.00 Cr
Hdfc Bank Limited₹716.88 Cr
Others₹550.00 Cr
The Hongkong and Shanghai Banking Corporation Limited₹350.00 Cr
Axis Bank Limited₹300.00 Cr
Others₹44.80 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
08 Apr 2026101282150Hdfc Bank Limited₹266.88 CrOpen
08 Apr 2026101283754The Hongkong and Shanghai Banking Corporation Limited₹300 CrOpen
12 Jan 2026101230130Idbi Trusteeship Services Limited₹10,990 CrOpen
07 Feb 2023100688815Idbi Trusteeship Services Limited₹400 CrOpen
02 Apr 2022100561525Hdfc Bank Limited₹450 CrOpen

To see the full charge records of Torrent Pharmaceuticals Ltd, buy the company report.

Total charge records: 65 View all charges

Deals & funding

Torrent Pharmaceuticals Ltd has 50 deals on record (37 market trades, 13 secondary share transfers); the latest was in January 2025.

Total deals
50
Market trades
37
Secondary share transfers
13

Deals on record (5 of 50)

WhenDealAmountParties
Oct 2024Market trade₹3,086.37 CrSeller: Torrent Investments Limited
Jul 2017Secondary share transferUndisclosedBuyer: Torrent Investments Limited , Hdfc Trustee Co Ltd Hdfc Multiple Yield Fund-Plan 2005, Birla Sun Life Trustee Company Private Limited A/C Birla Sun Life Balanced 95 Fund
Seller: Sudhir U Mehta HUF, Others-Torrent Pharmaceuticals Limited, 2 individuals
Jul 2009Secondary share transferUndisclosedBuyer: Torrent Investments Limited
Seller: Others-Torrent Pharmaceuticals Limited, Franklin Templeton Mutual Fund A/C Franklin India Prima Fund
Nov 2007Market trade₹19 CrBuyer: Icici Securities Primary Dealership Limited
Seller: Templeton Mutual Fund Ac Franklin India Prima Plus Ac 4616
Oct 2007Market trade₹96.72 CrBuyer: Icici Securities Primary Dealership Limited
Seller: Mavi Investment

To see the full deal history of Torrent Pharmaceuticals Ltd, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Torrent Pharmaceuticals Ltd was last rated by Icra on 30 Aug 2021.

Rating agencyRated onRating
Icra30 Aug 2021

To see the full credit ratings and regulatory alerts of Torrent Pharmaceuticals Ltd, buy the company report.

MSME payment delays

Torrent Pharmaceuticals Ltd has 12 MSME Form 1 returns on record between 2018 and 2024, listing 185 overdue payments to 76 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 76)

SupplierAmount dueDue sinceReported on
an individual supplier
June Enterprises Private Limited
Raj Barcode Systems Private Limited
Satya Packaging
Vishruta Packaging Private Limited

To see the full MSME payment records of Torrent Pharmaceuticals Ltd, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Torrent Pharmaceuticals has 1 associated company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Associated companies

Employees & EPFO

Torrent Pharmaceuticals Ltd has a workforce of 15,615 employees on its EPFO records as of Mar 10, 2025, across 8 active EPFO establishments.

Employee count
15,615
Active EPFO establishments
8
Employee growth
6.46%

GST

Torrent Pharmaceuticals has 40 GST registrations: 25 active and 15 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
40
Active
25
Cancelled / inactive
15
GSTINStateStatusRegistered on
24AAACT5456A1ZRGujaratActive01 Jul 2017
24AAACT5456A2ZQGujaratActive01 Jul 2017
24AAACT5456A3ZPGujaratActive19 Jul 2017
02AAACT5456A1ZXHimachal PradeshActive01 Jul 2017

To see the full GST registrations and return filing status of Torrent Pharmaceuticals Ltd, buy the company report.

Recent activity

Torrent Pharmaceuticals Ltd has 50 board changes on record since 1982: 29 appointments and 21 cessations. The latest: Aman Samir Mehta was appointed as Managing Director on 31 Jul 2025.

Charges
A charge registered on 05 Apr 2013 via Charge ID 10421600 with Bnp Paribas was fully satisfied on 11 Jun 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 266.88 Cr with Charge ID 101282150 was registered on 08 Apr 2026.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited amounted to Rs. 300.00 Cr with Charge ID 101283754 was registered on 08 Apr 2026.
Charges
A charge with Idbi Trusteeship Services Limited of Rs. 400.00 Cr registered on 07 Feb 2023 with Charge ID 100688815 was modified on 08 Apr 2026.
Filing
Torrent Pharmaceuticals Ltd has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Ahmedabad.
Charges
A charge registered on 12 Oct 2018 via Charge ID 100212700 with Idbi Trusteeship Services Limited was fully satisfied on 05 Feb 2026.
Charges
A charge with Idbi Trusteeship Services Limited amounted to Rs. 10,990.00 Cr with Charge ID 101230130 was registered on 12 Jan 2026.
Charges
A charge registered on 16 Mar 1988 via Charge ID 90314072 with State Bank Of Inida was fully satisfied on 09 Jan 2026.
Charges
A charge registered on 05 May 2005 via Charge ID 90103831 with Citibank N.A. was fully satisfied on 08 Jan 2026.
Charges
A charge registered on 13 Mar 2018 via Charge ID 100201579 with Idbi Trusteeship Services Limited was fully satisfied on 12 Dec 2025.
Charges
A charge registered on 24 Feb 2023 via Charge ID 100683495 with Hdfc Bank Limited was fully satisfied on 31 Oct 2025.
Charges
A charge registered on 26 Apr 2018 via Charge ID 100173917 with Idbi Trusteeship Services Limited was fully satisfied on 01 Oct 2025.

201 earlier events are in the company report.

News

TORNTPHARM: Rs. 27.78 Crores BSE Block Trade; for ~ 60,000 Shares, at Rs. 4630.00
27 Oct 2026 · Exchange Update
Torrent Pharma: Kotak Institutional Equities on Torrent Pharma Upgrades to Buy, Target Price ₹5,665; Q2 was in line, with strong double-digit base-business growth offset by slower JB Pharma, Germany and higher R&D costs. JB cost synergies reached ₹1.2bn in H1, ahead of schedule, with revenue synergies expected from Q1FY28; forecasts 19% FY26–29 EBITDA CAGR.
26 Oct 2026 · Exchange Update
Torrent Pharma: HSBC on Torrent Pharma Maintains Buy, Target Price ₹5,700; base India sales excluding JB Pharma rose 20% YoY, while JB performance was affected by post-merger integration. Branded-generics growth should support margin expansion, and recovery in JB Pharma's portfolio is the next catalyst.
26 Oct 2026 · Exchange Update
Torrent Pharma: Citi on Torrent Pharma Maintains Buy, Target Price ₹5,860; Q2 was in line, with strong India and Brazil performance offset by temporary JB integration and delayed international deliveries. Management expects gradual JB recovery and improving H2 India growth; around half of the ₹4.5bn synergies are expected in FY27, with the balance in FY28.
26 Oct 2026 · Exchange Update
Torrent Pharma: Jefferies on Torrent Pharma Maintains Buy, Target Price ₹5,900; India base business grew 20% YoY and Brazil delivered 21% constant-currency growth, while US growth remained steady. JB integration is ahead of schedule, with half of cost synergies achieved and revenue synergies expected to support next year's growth.
26 Oct 2026 · Exchange Update
Torrent Pharma: Nomura on Torrent Pharma Maintains Neutral, Target Price ₹5,030; Q2 headline performance slightly missed expectations, but core business remained strong. The company now expects ₹4.5bn of JB Pharma acquisition synergies over two years instead of three, with margins expected to improve slightly in H2FY27 as operations stabilise.
26 Oct 2026 · Exchange Update

From our blog

Frequently asked questions

Torrent Pharmaceuticals is an active public limited company based in Ahmedabad, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 15 July 1972 (54+ years old) and is registered under CIN L24230GJ1972PLC002126. Listed on BSE: 500420 and NSE: TORNTPHARM.

Torrent Pharmaceuticals reported revenue of ₹19,274 Cr for FY 2025-26 (up 67.4% YoY) based on consolidated financials.

Torrent Pharmaceuticals has 7 current directors:

The latest financial statements of Torrent Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 28 July 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Torrent Pharmaceuticals is 24AAACT5456A1ZR, registered in Gujarat. The company has 40 GST registrations in all, of which 25 are active and 15 are cancelled or inactive. Other active GSTINs include 24AAACT5456A2ZQ (Gujarat), 24AAACT5456A3ZP (Gujarat), 02AAACT5456A1ZX (Himachal Pradesh).

The CIN (Corporate Identification Number) of Torrent Pharmaceuticals is L24230GJ1972PLC002126. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Torrent Pharmaceuticals is a listed company as per MCA records. Its shares are listed on both BSE (code: 500420) and NSE (symbol: TORNTPHARM).

Torrent Pharmaceuticals has 472 court cases on record: 219 filed by the company and 253 filed against it. 138 are pending. Most are in the high courts.

Torrent Pharmaceuticals was incorporated on 15 July 1972, making it 54+ years old. It is registered with the Registrar of Companies, Ahmedabad.

Torrent Pharmaceuticals has 50 deals on record (37 market trades, 13 secondary share transfers); the latest was in January 2025.

The peers of Torrent Pharmaceuticals by revenue are Hetero Labs Limited, Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Serum Institute of India Private Limited and 4 more, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Aman Samir Mehta was appointed as Managing Director on 31 Jul 2025. Maurice Antoine Rene Chagnaud ceased to be Director on 10 May 2025. Jinesh Dushyant Shah ceased to be Director on 23 Jul 2024. Torrent Pharmaceuticals has 50 board changes on record in total.